Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.

David T RubinWalter ReinischThomas GreuterPaulo Gustavo KotzeMarcia PinheiroRajiv MundayatEric MallerMarc FellmannNervin LawendyIrene ModestoStephan R VavrickaGary R Lichtenstein

Published in: Therapeutic advances in gastroenterology (2021)

Any history of EIMs did not influence the efficacy of tofacitinib 10 mg BID for induction or maintenance of UC. The most common active EIM was peripheral arthritis, for which many patients in OCTAVE Induction 1 and 2, and OCTAVE Sustain, reported improvement or no change from baseline with tofacitinib treatment.Clinicaltrials.gov:NCT01465763; NCT01458951; NCT01458574.

Keyphrases

ulcerative colitis
rheumatoid arthritis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
early onset
high intensity